National Cancer Institute, Kyiv 03022, Ukraine.
Exp Oncol. 2020 Jun;42(2):140-143. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-2.14579.
At present, there are no valid prognostic biomarkers in patients with triple negative breast cancer (TNBC) except well known clinical factors such as tumor size, lymph node status, differentiation grade and proliferation rate.
To evaluate the prognostic role of androgen receptor (AR) expression in patients with TNBC.
The effect of the AR expression level in tumor tissue on overall survival depending on clinical, histological and immunohistochemical characteristics of the tumor was evaluated in 116 patients with metastatic TNBC.
The independent prognostic value of AR expression in patients with TNBC of different stages was shown. The median overall survival was higher in patients with AR-positive tumors compared with AR-negative tumors (57 months vs 27 months, p < 0.0001). Five-year survival since diagnosis in the group with AR-positive TNBC was 47.6 ± 8.3% vs 20.0 ± 5.3% in the group with AR-negative TNBC (p < 0.05).
The results of our study indicate a favorable impact of AR expression on the overall survival of TNBC patients.
目前，三阴性乳腺癌（TNBC）患者除了肿瘤大小、淋巴结状态、分化程度和增殖率等已知的临床因素外，没有有效的预后生物标志物。
评估雄激素受体（AR）表达在 TNBC 患者中的预后作用。
评估了 116 例转移性 TNBC 患者肿瘤组织中 AR 表达水平对总生存期的影响，根据肿瘤的临床、组织学和免疫组织化学特征进行评估。
显示 AR 表达在不同分期的 TNBC 患者中的独立预后价值。与 AR 阴性肿瘤相比，AR 阳性肿瘤患者的中位总生存期更高（57 个月比 27 个月，p < 0.0001）。AR 阳性 TNBC 组的 5 年生存率为 47.6 ± 8.3%，而 AR 阴性 TNBC 组为 20.0 ± 5.3%（p < 0.05）。
我们的研究结果表明 AR 表达对 TNBC 患者的总生存期有有利影响。
